GALT Galectin Therapeutics Inc.
Healthcare$2.79+11.60%ClosedMarket Cap: $183.7M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-1.26
P/S
0.00
EV/EBITDA
-14.57
DCF Value
$-1.86
FCF Yield
-12.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
21.0%
ROA
-166.6%
ROIC
-192.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-4.1M | $-5.0M | $— | — |
| Q4 null | $0.00 | NaN% | $-3.4M | $-5.5M | $— | — |
| FY null | $0.00 | NaN% | $-20.1M | $-30.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-4.2M | $-8.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-4.6M | $-7.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-7.9M | $-9.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-12.4M | $-12.0M | $— | — |
| FY null | $0.00 | NaN% | $-42.4M | $-47.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-9.1M | $-11.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-11.3M | $-12.4M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-9.6M | $-11.5M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-9.6M | $-10.0M | $-0.16 | — |